Corticosteroids have the major role in the immunosuppressive treatment of patients who have received renal transplants. Despite their extensive use there is still debate about the appropriate dose that will prevent rejection of the renal allograft with the least morbidity. From March 1979 to November 1981 a randomised controlled trial of high (33 patients) v low oral dose (34 patients) of prednisolone along with azathioprine was conducted in recipients of first cadaveric transplants who had received a blood transfusion within six months of transplantation. The main difference in outcome between the two groups was a high incidence of some infections in the high dose group. Patient mortality, graft survival, transplant function, and number of rejection episodes were indistinguishable in the two groups, but rejection episodes tended to occur later in the high dose group.
Introduction
Since 1963, when Goodwin et al reported the use of corticosteroids in the immunosuppressive treatment after human renal transplantation,' corticosteroids and azathioprine have been the main chemical immunosuppressive agents used in recipients of renal transplants. Despite extensive use of corticosteroids, the optimal dose for the prevention of graft rejection with the least side effects has not been established. High doses of steroids are still used in several units in the early months after transplantation before maintenance doses of 10-20 mg/24 h are established.
On the other hand, the use of low dose steroids from the outset has been supported strongly by the excellent results of McGeown et all -who used 20 mg of prednisolone from the day after transplantation. This is reinforced by the findings of Kreis et al, who avoided the use of steroids altogether immediately after transplantation, and believed that in the absence of obvious rejection some patients may not need corticosteroids at all.5
Recently Buckels et a16 and Morris et al,' in prospective trials in recipients of cadaveric kidneys, compared the use of high dose and low dose steroids and reported that the use of low doses of prednisolone from the day after transplantation does not jeopardise graft survival and results in lower morbidity.
We conducted a prospective trial of high versus low dose corticosteroids in patients receiving first cadaveric transplants. Our purpose was to see if there were differences between the two regimens in their ability to prevent rejection, and in the mortality and morbidity which they induced in patients who had received renal transplants. Figure 1 shows the schedule of steroids that was given to the patients: 33 patients received the high dose and 34 the low dose. The daily dose of corticosteroids was given in two divided doses, the evening dose gradually being phased out as dosage was reduced. All patients also received azathioprine, 2-5 mg/kg/day, which was omitted temporarily in the presence of leucopenia ( < 5000 white blood cells/,ul). Acute rejection episodes were treated in both groups with 1 g methylprednisolone given intravenously on three consecutive days.
BRITISH MEDICAL JOURNAL VOLUME 286 2 APRIL 1983 ANALYSIS OF OUTCOME The two groups were compared for factors that could influence graft survival-sex, age primary renal disease, HLA-A and HLA-B mismatches, blood group, and parity. All patients had received at least 5 units of 10 day old blood before transplantation. Patient mortality, graft survival, renal function as estimated by the plasma creatinine concentration (tmol/l), the number of rejection episodes, and the day of onset of the first rejection episodes were compared in the two groups.
ANALYSIS OF COMPLICATIONS
The incidence of infections, which were divided into urinary tract infections, chest infections, and "others" was analysed. Other infections included wound infection; bacterial infections in sites apart from the urinary tract, the lung, and the wound; positive blood cultures; cytomegalovirus infections; herpes virus infections; and pyrexia of undetermined origin. We also recorded the incidence of other complications that might be attributed to corticosteroids, such as avascular necrosis of bone, alimentary tract complications, steroid induced diabetes, and cataracts. Finally, the rate of healing of the transplant wound and the duration of hospital admission during and after transplantation were compared.
STATISTICAL METHODS
The life table method8 was used to analyse the survival of grafts and of patients, the time to first rejection, and the time to discharge from hospital. The Cox-Mantel logrank test was used to test the differences. The x2 method was used to assess possible differences in the composition of the two groups, the infection rates and possible steroid related complications. Student's t test was used to test the differences in ages of the two groups, the total number of rejection episodes, and the number of episodes in the first month, and the plasma creatinine concentrations in surviving grafts.
Results
There was no difference between the groups (p < 0-05) in all factors believed to influence graft survival (table II) . (25) 3 (9) 6 (18) 1 (3) 5 (15) 10 (30) 14 (42) 11 (33) 8 (25) 10 (30) 18 (54) 5 (16) 6 (50) 6 (50) 24 10 44 4 15-4 (SD)
13 (38) 2 (6) 7 (20) 6 (18) 1 (3) 5 (15) 8 (24) 12 (35) 14 (41) 14 (41) 15 (44) 5 (15) 6 (60) (----) . Data from patients who were withdrawn from the trial (see text) were used up to point of withdrawal, and deaths of patients with functioning graft were noted as cessation of follow up in calculating graft survival.
GRAFT SURVIVAL AND FUNCTION
Thirteen grafts of the 33 were lost in the high dose group and 10 of the 34 in the low dose group. Survival rates calculated actuarially at two years were 55% for the high dose group and f68% for the low dose group (fig 2) . There was no difference between these two sets of data on logrank testing (p=0 12), and a less than 0-05 chance that these data are compatible with a true reduction in graft survival of 20% (X2=3-88), the initial target of the trial. There is, however, a 1 in 5 chance that a smaller reduction in graft survival might occur at the 10% level, and this possibility is not excluded by our data because of the small numbers entered.
In the life table analysis the grafts of the patients who died with functioning grafts, as well as those of the patients who were withdrawn from the trial, were considered as functioning grafts with duration of function equal to the time that they were followed up in the trial.
There was no difference between the groups in the renal function of the patients with functioning grafts, as shown by plasma creatinine concentrations ( fig 3) . 
REJECTION EPISODES
There was no difference between the two groups in the total number of rejection episodes or in the number of rejection episodes occurring during the first three months after transplantation. There was, however, a significant difference in the time to first rejection episodes (p < 0 05) and in number of rejection episodes during the first month after transplantation, during which period more rejection episodes were diagnosed in the low dose group (p 0-05) (table III) . 
COMPLICATIONS
Infections were the most frequent complication in both groups, although no patient died of it. There was no significant difference in the number of patients who presented with urinary tract infections or chest infections, although their incidence was greater in the patients receiving high dose. A significant difference was found in the number of patients in the high dose group with "other" infections (table VI) ; table V shows the actual numbers and types of these infections, with a higher incidence of almost all types of infection in the high dose group.
The incidence of other complications that might be attributed to corticosteroids was not significantly different in the two groups, although their incidence was greater in the higher dose group (table  VI) .
Wound healing and admission to hospital-By 15 days after operation, 21 wounds had healed in the high dose group and 30 in the low dose group (p < 0-05). No significant difference was found in the time that the patients in the two groups spent in hospital during and after the transplantation (fig 4) by the logrank analysis (p->0 10) although the six patients with the longest stay were all receiving the high dosage regimen. 
Discussion
Renal transplantation has become the treatment of choice in end stage renal failure as it has led to excellent rehabilitation of patients9 and is cheaper than dialysis.10 The problems of morbidity and graft failure, however, have by no means been resolved. A "safe" immunosuppressive regimen would probably be the key to their solution. This, for the present, means the optimal use of azathioprine and corticosteroids, although the impact of cyclosporin'1 may yet be considerable. Debate concerning the optimum dose of corticosteroids continues, and many units follow the policy that "more is best," although several reports-including our own-support the idea that lower doses are equally effective.2-4 6 7
Our trial was conducted at about the same time as the trials in Birmingham6 and Oxford, 7 but in some ways is superior in design. Our corticosteroid dose was based on bodyweight, all the patients were receiving first cadaveric transplants, and all had received transfusions before transplantation. In the Birmingham trial the doses of corticosteroids were fixed, so that the corticosteroid activity could be influenced by the patient's bodyweight. Not all their patients had had transfusions, and some had received more than one allograft. In the Oxford trial the doses of corticosteroids were also fixed, and the patients in the low dose group routinely received 1 g of intravenous methylprednisolone on the sixth, seventh, and eighth day after transplantation, and the gap between the two regimens may have been decreased by this. Some of their patients had received more than one allograft, and only 6001" of them had had transfusions before transplantation. Our rate of survival for patients and grafts is, however, similar to those of the other two groups, and not different to those of other units.2 This must be seen in relation to the fact that our patients were older-about half were over 45 and a quarter over 60-and that all patients received the same corticosteroid dosage from 12 weeks onwards.
The analysis of graft survival and the study of renal function showed that the low doses of corticosteroids used appear to cover the patients from the danger of loss of function in their grafts to the same extent as higher initial doses. In fact, the results were better in the low dose group, though not statistically significant. Because of small numbers, our data cannot exclude the possibility of a smaller reduction in graft survival at the 10"' level,"' although we have excluded the possibility of a 20%' reduction.
Four deaths were asymmetrically distributed, three being in the low and one in the high dose group, but again this does not reach significance; examination of the circumstances of death suggests that at least two were coincidental and unrelated to treatment. The zero mortality in patients under the age of 45 was gratifying. The number of acute rejection episodes was indistinguishable between the two groups, but the time to first rejection was longer and the number of rejection episodes in the first month lower in the high dose group. This postponement of early rejection did not seem to affect long term survival of the grafts.
Both bacterial and viral infections outside the respiratory and urinary tracts were more common in the high dose group. It is accepted that there is a direct relation between the incidence of infection and the quantity of immunosuppressive treatment in patients who have received renal transplants.'0 1 Because the rest of the immunosuppressive treatment was the same in the two groups, the greater incidence of almost all the infections in the patients in the high dose group must be attributed to the higher dose of corticosteroids that was given to them.
The morbidity from the other complications that may be attributed to corticosteroids was not different in the two groups, although it is noteworthy that again more patients in the high dose group were affected by them. Analysis of the number of transplant incisions healed within 15 days of transplantation showed that wounds of the patients in the high dose group needed longer to heal. This may be partially due to the increased incidence of wound infections in the high dose group, because most wound infections were infections of the transplant incision. We cannot, however, exclude a direct influence of corticosteroids in this prolongation of the time to healing, a fact which contributes to the patients' morbidity.
Our results clearly show that low doses of corticosteroids, with azathioprine, were not only sufficient as immunosuppressive treatment but they also led to less morbidity in the patients. Since this trial has finished, we have continued the low dose regimen in all our patients receiving renal transplants. To determine whether even lower doses of corticosteroids could be used with even greater safety and comparable (or better) results will require a further trial.
